Insulin Pump Denied by Insurance: How to Appeal and Get Your CGM-Integrated Pump Covered

An insulin pump (continuous subcutaneous insulin infusion, or CSII) is a small device worn on the body that delivers a continuous basal rate of rapid-acting insulin plus bolus doses at meals, replacing multiple daily injections (MDI) with more precise and flexible insulin delivery. For many people with type 1 diabetes and some with insulin-dependent type 2 diabetes, an insulin pump dramatically improves glycemic control, reduces hypoglycemia, and improves quality of life. Insurers deny insulin pump coverage routinely — but these denials are highly appealable when properly documented.

Why Insulin Pumps Get Denied

Type 1 vs. type 2 criteria. Most insurers have liberal coverage policies for insulin pumps in type 1 diabetes but impose strict additional requirements for type 2. For type 2, requirements often include documented failure to achieve glycemic targets despite aggressive basal-bolus MDI therapy, demonstration of insulin dependence, and sometimes a minimum number of daily injections already in use.

C-peptide testing. C-peptide is a marker of residual beta-cell function. A low fasting C-peptide (often < 0.5 ng/mL) confirms type 1 diabetes or absolute insulin deficiency. Many insurers require C-peptide testing before approving a pump — particularly for patients with type 2 diabetes — to verify genuine insulin dependence. If C-peptide was not included in the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization request, the denial often cites this gap.

HbA1c and glycemic control documentation. Insurers typically require documentation of inadequate glycemic control despite multiple daily injections (MDI). This usually means HbA1c above target (often > 7.5%–8%) or documented recurrent hypoglycemia. Conversely, some insurers deny pumps for patients whose HbA1c is well-controlled on MDI, arguing a pump is not necessary. In those cases, the appeal should document hypoglycemia frequency and unawareness as the clinical justification.

Carbohydrate counting training requirement. Effective pump therapy requires carbohydrate counting to program accurate mealtime boluses. Many insurance policies require documentation that the patient has completed formal carbohydrate counting or diabetes self-management education (DSME) training. If this isn't in the records, it's a common denial reason.

CGM integration. Modern closed-loop systems (Omnipod 5, Tandem Control-IQ, Medtronic MiniMed 780G) integrate continuous glucose monitors (CGMs) to automate insulin delivery. Insurers sometimes require a separate prior authorization for the CGM component versus the pump itself, and denials occur when both are not pre-authorized simultaneously.

Building Your Insulin Pump Appeal

Document insulin regimen and failure. Your appeal should include:

• Current insulin regimen (basal insulin type, dose, frequency; rapid-acting insulin name, dose, correction factor)
• Most recent HbA1c and frequency of blood glucose monitoring
• Documentation of hypoglycemia — specifically frequency, severity, any episodes of severe hypoglycemia requiring assistance, and any hypoglycemia unawareness

Include C-peptide results. If C-peptide was not included in the original PA request, have your endocrinologist order the test now and include results in the appeal. For type 1 patients, a low C-peptide (< 0.5 ng/mL fasting, or < 0.2 pmol/mL stimulated) confirms absolute insulin deficiency.

Document patient education completion. Attach certificates or chart notes confirming completion of diabetes self-management education, carbohydrate counting training, or insulin adjustment education. If training has not been completed, your endocrinologist can document that training will occur concurrent with pump initiation.

Cite clinical benefit data. Published literature demonstrates that pump therapy reduces HbA1c, reduces severe hypoglycemia frequency, and improves time-in-range compared to MDI in appropriate patients. The JDRF randomized trial and multiple real-world studies support this. Your endocrinologist can reference these studies in the medical necessity letter.

For recurrent hypoglycemia. If the clinical justification is hypoglycemia rather than hyperglycemia, document:

• Number of hypoglycemic episodes per week (blood glucose < 70 mg/dL or < 54 mg/dL)
• Any severe episodes requiring glucagon administration or emergency services
• Hypoglycemia unawareness confirmed by loss of adrenergic warning symptoms
• Failure of adjusted basal insulin timing and dose modifications to prevent hypoglycemia

Medicare Coverage for Insulin Pumps

Medicare covers insulin pumps under the durable medical equipment (DME) benefit (Part B) when:

• C-peptide level ≤ 110% of lower limit of normal fasting
• Patient has type 1 or insulin-dependent type 2 diabetes
• HbA1c > 7% while on at least three daily insulin injections
• Patient has been educated in insulin pump management

Ensure the prescribing endocrinologist provides documentation matching all four Medicare criteria. Incomplete documentation is the most common cause of Medicare insulin pump denials.

Fight Back With ClaimBack

An insulin pump denial doesn't have to mean going back to multiple daily injections. ClaimBack helps you organize the clinical documentation — HbA1c history, C-peptide, hypoglycemia records, and education certificates — into a compelling appeal.

Start your insulin pump appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied